show episodes
 
Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing urologists and radiation oncologists ongoing access to the perspectives and opinions of national and international prostate cancer research leaders.
  continue reading
 
Artwork

1
GU Cast

Professor Declan Murphy & Dr Renu Eapen

Unsubscribe
Unsubscribe
Monthly+
 
A urology podcast, focussing on all things prostate, kidney, bladder, testis and penile cancer. Join Professor Declan Murphy and Dr Renu Eapen from Peter MacCallum Cancer Centre in Melbourne for this regular dive into the world of genitourinary (GU) Oncology and Urology. Regular guests from all over the world, from every walk of life. Find out more gucast.org
  continue reading
 
CancerCare's free Connect Education Workshops are a way for people to learn about cancer-related issues from the convenience of their home or office. Leading experts in oncology provide the most up-to-date information in these workshops to help you and your loved ones better understand and cope with your cancer diagnosis, treatment options, quality-of-life concerns, treatment side effects, pain management, doctor-patient communication and other important topics.
  continue reading
 
Artwork

1
CCO Oncology Podcast

Clinical Care Options

Unsubscribe
Unsubscribe
Monthly+
 
Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
  continue reading
 
Editors at The Lancet Oncology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy. A monthly audio companion to the journal, this podcast covers a broad range of topics, from early-stage breast cancer treatment to mRNA vaccines, the access to essential cancer medicines for children to measuring ovarian toxicity, and more.
  continue reading
 
Interviews with authors of articles from JAMA Oncology. JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and sta ...
  continue reading
 
OUR MISSION To facilitate tangible improvements in the lives of people who have been affected by cancer(s), by providing them and their loved ones the necessary survival tools, education, support and advocacy so that they can become responsible for and take an active role in their own medical care and wellbeing. OUR GOAL Our goal is to teach all people affected by cancer, including those with multiple cancers and/or rare cancers, to become CANCER THRIVERS.
  continue reading
 
Loading …
show series
 
Pelvic lymph node dissection down-graded. Systematic prostate biopsies no longer recommended. More clarity around PSMA PET/CT for staging. Surgery no longer recommended for cN1 prostate cancer. Yep the recent updates to the EAU Prostate Cancer Guidelines had a lot of important changes for the global urology community to digest. So we invited EAU Pr…
  continue reading
 
The first of two Conference Highlight specials from the Advanced Prostate Cancer Consensus Conference, held in April 2024 in Lugano. This is our very favourite prostate cancer meeting and we are thrilled to bring you these highlight podcasts. In this epsiode we chat with Silke Gillessen, Derya Tilki, Jochen Walz, Neha Vapiwala, Dingwei Ye, and the …
  continue reading
 
Didn't get to ASCO this year?? Us neither!! But not to worry, we checked in with Dr Marty Schoen who did, and brings us all the key highlights! Marty is a GU Medical Oncologist at the St Louis Veterans Affairs Medical Centre and the University of St Louis, Missouri. He runs through a smattering of stuff that caught his eye at ASCO this year. Thanks…
  continue reading
 
Dr Matthew Galsky from The Tisch Cancer Institute in New York and Dr Ashish Kamat from The University of Texas MD Anderson Cancer Center in Houston summarize recent clinical advances in the management of urothelial bladder cancer, including data from the 2024 AUA annual meeting.By Neil Love, MD
  continue reading
 
For Urologists, there are not that many papers that come along where we can say - "this will almost immediately change my practice". But KEYNOTE-564 looks like one of those! A large phase III randomised trial of adjuvant pembro following nephrectomy for renal cell carcinoma in patients deemed at higher risk for recurrence. Regular listeners/viewers…
  continue reading
 
Should we remove bladder cancers piece-meal by chopping them into little pieces, or should we try and remove en bloc with a margin around the base?? This very nice randomised controlled trial from our friends in Hong Kong demonstrates that the recurrence rate is significantly lower if we use the all-too-rarely used en bloc technique. Dr Jeremy Teoh…
  continue reading
 
Dr Garth Strohbehn (Veteran Affairs Center for Clinical Management Research, Ann Arbor, Michigan, USA) and Dr Katie Lichter (University of California, San Francisco, USA) discuss their papers on the environmental impact of cancer treatments and the public harms resulting from it. Tell us what you thought about this episode Continue this conversatio…
  continue reading
 
1. Immunohistochemistry of urothelial cancer 2. History of systemic therapy in advanced and metastatic disease 3. Pembrolizumab and Enfortumab Vedotin 4. Approach to second line therapy and beyond Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly enc…
  continue reading
 
Today we have Dr Alicia Morgans, GU Medical Oncologist and Director of Survivorship at Dana Farber Cancer Institute, in the GU Cast studio for a chat. We wanted to ask Alicia to look forward and identify three big challenges we will face in metastatic prostate cancer over the next 5-10 years. What did we come up with??!! Tune in to find out!! Even …
  continue reading
 
In this episode, Manali Bhave, MD; Annalise Labatut, PharmD, BCOP; and nurse practitioner Jamie L. Carroll, CNP, APRN, MSN, begin by discussing the landmark EMERALD study that led to FDA approval of elacestrant, the first oral selective estrogen receptor degrader (SERD) for treatment of hormone receptor–positive/HER2-negative metastatic breast canc…
  continue reading
 
- Definition of a Caregiver- What Research Tells Us About Caregivers’ Well Being- Caregiving for an Older Adult- Caregiving for a Younger Adult- Couples, Partners, Siblings, & Friends- Challenges for Caregivers of Cancer Survivors- Family, Partner, & Friend Communication- Care Coordination Challenges & Tips- Stresses on Family, Partners, Friends, &…
  continue reading
 
In the first of our special episodes focussing on GU Oncology in China, we are delighted to welcome our inaugural GU Cast China Editor. Professor Yao Zhu, to the GU Cast studio. Yao is a Urologist at Fudan University Shanghai Cancer Centre, and is well known to all of us at GU Cast and Peter MacCallum Cancer Centre. As part of our Gold Partnership …
  continue reading
 
Dr Matthew D Galsky from Icahn School of Medicine at Mount Sinai in New York, New York, summarizes treatment options for patients with HER2-altered genitourinary cancers and reviews recent emerging clinical trial data in the field.By Neil Love, MD
  continue reading
 
In this episode, Danielle M. Brander, MD; Deborah Stephens, DO; and Brian Hill, MD, PhD, discuss key aspects of the NCCN CLL guidelines and share strategies for applying these recommendations in your clinical practice to optimize treatment and outcomes. The greater discussion addresses: Optimal selection of therapy for treatment-naive CLL, includin…
  continue reading
 
Dr James Shultz, (University of Miami Miller School of Medicine, Miami, USA), Dr Ana Patricia Ortiz (University of Puerto Rico, and University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico), and Dr Leticia Nogueira (American Cancer Society, Georgia, USA) discuss their Personal View entitled, ‘Protecting Caribbean patients diagno…
  continue reading
 
Great fun on the shores of Lake Lugano where the hosts of three of the best -known podcasts in GU Oncology get together for a chat! Declan and Renu from GU Cast, join with Brian and Tom from Uromigos, and Gill from Oncoalert. How did it all start? Why did it all start?! Best moments, worst moments etc. Tune if for a chat, and do please subscribe/li…
  continue reading
 
Dr Emmanuel Antonarakis from the University of Minnesota in Minneapolis reviews research findings presented at the 2024 Genitourinary Cancers Symposium and provides his perspectives on current and novel treatment approaches for prostate cancer.By Neil Love, MD
  continue reading
 
As April is bowel cancer awareness month we are delighted to have a bonus episode for our listeners. We are joined by Carmel Drohan who was diagnosed with stage 4 bowel cancer in 2015 and she talks us through her experience to date. Carmel has had multiple surgerys and chemotherapy treatments and we are extremely grateful to her for sharing her sto…
  continue reading
 
- How Being a Member of Diverse Communities May Impact Your Access to Oncology Care, Treatment, Management of Treatment Side Effects & Pain Management- What to Expect from Your Relationship with Your Health Care Team: Is Your Health Care Team Providing You with Equitable, Excellent Care- What to Consider When Selecting a Cancer Care Team & Treatmen…
  continue reading
 
1. Etymology, presentation, and work-up of bladder/urothelial cancer 2. Role of perioperative systemic therapy 3. Tri-modality therapy (bladder sparing approach) 4. Considerations for upper tract urothelial cancer Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.c…
  continue reading
 
The 2nd ProsTIC Preceptorship is one of the most intense fora for the discussion of PSMA theranostics anywhere in the world! A biennial meeting in Melbourne with many of the world's leading experts in the field. Not just superb practical advice about how to get your prostate cancer theranostics program to the next level, but some amazing discussion…
  continue reading
 
1. Clinical presentation and work-up 2. Intestinal and pancreatobiliary subtypes 3. Role of perioperative therapy 4. Considerations for metastatic disease Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by A…
  continue reading
 
Dr Bernardo Goulart (US Food and Drug Administration) discusses his paper on correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00040-8/fulltext?dgcid=buzzsprout_…
  continue reading
 
- Overview of Common Eye & Vision Changes Related to Cancer Treatments- Discussion of Common Eye & Vision Changes, Including Causes & Risk Factors- Tips to Manage Dry Eyes, Watery Eyes, Itching Eyes, Blepharitis, Loss of Eyelashes, Changes in Vision, Cataracts, Floaters, & Flashing Lights- The Role of the Multidisciplinary Team- Tips to Manage Low …
  continue reading
 
Dr Shilpa Gupta from the Taussig Cancer Institute in Cleveland, Ohio, and Prof Thomas Powles from the Barts Cancer Institute in London, United Kingdom, discuss clinical decision-making with numerous treatment strategies for urothelial bladder cancer.By Neil Love, MD
  continue reading
 
A new paper in the Journal of Clinical Oncology is reporting that the bowel and urinary side-effects of proton therapy (a high tech and very expensive type of radiotherapy), are no better than side-effects after standard high-quality radiotherapy (called IMRT). Quite a fuss on twitter when this paper came on line last week including from a fair few…
  continue reading
 
Professor Neil Fleshner (University of Toronto) drops into the GU Cast studio in Melbourne for an intriguing discussion! First we cover off the underrated topic of cardiac risks in patients starting androgen deprivation therapy and how we can reduce these for the benefit of our patients. Then we talk to Neil about entrepreneurship and his journey i…
  continue reading
 
In this episode, Colin C. Pritchard, MD, PhD, a pathologist, and Heather H. Cheng, MD, PhD, a medical oncologist, discuss optimal biomarker testing to guide treatment decisions in advanced prostate cancer, with topics including: Rationale for targeting PARP in prostate cancer with ARI combinations Study design nuances and findings from key randomiz…
  continue reading
 
Dr Andrew J Armstrong from the Duke Cancer Institute Center in Durham, North Carolina and Dr Maha Hussain from Robert H Lurie Comprehensive Cancer Center in Chicago summarize recent data sets from 2023 on hormonal therapies and other emerging treatment approaches for patients with prostate cancer.By Neil Love, MD
  continue reading
 
A big medical oncology love-in in the GU Cast studio today!! Professor Enrique Grande was visiting from MD Anderson Cancer Centre in Madrid to chat all about some of the sensational advances we have seen in metastatic bladder cancer in recent times. And we were also joined by old friend Professor Andrew Weickhardt from Austin Health in Melbourne to…
  continue reading
 
Interview with Tobias Janowitz, MD, PhD, and Karen Winkfield, MD, PhD, authors of Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time. Hosted by Vivek Subbiah, MD. Related Content: Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time…
  continue reading
 
Axel Merseburger (Chief and Professor of Urology, Lubeck, Germany) was in Australia recently and popped into the GU Cast studio for a chat. Axel was at the USANZ ASM recently and also on a speaker tour supported by Janssen Pharmaceuticals, so we put together this Themed Podcast to pick his brains on high-risk prostate cancer and mHSPC in 2024. This…
  continue reading
 
In this podcast episode, Sara M. Tolaney, MD, MPH, and Melinda Telli, MD, delve into the critical aspects of the current therapeutic landscape for patients with unresectable or metastatic HER2-low, hormone receptor–positive, and triple-negative breast cancer, including: Challenges with the pathologic testing for HER2-low expression Optimal treatmen…
  continue reading
 
Drs Petros Grivas, Vadim S Koshkin, Kriti Mittal, Mamta Parikh and Scott T Tagawa discuss available and emerging research, patient cases from participating junior clinical investigators and the perspectives of senior clinical investigator faculty on data informing their decision-making for patients with metastatic urothelial bladder cancer.…
  continue reading
 
In a special episode on International Women's Day 2024, we speak with Dr Maria Kyrgiou (Imperial College London, London, UK) about her Essay on innovations and disparities in gynaecological cancer care. Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://twitter.com/thelancet & https://Twi…
  continue reading
 
Declan and Renu bring you lots of highlights and interviews from the Urological Society of Australia & New Zealand (USANZ) Annual Scientific Meeting (ASM) which took place last week in Adelaide. Almost 1000 delegates descended on this beautiful part of the world, famous for its beaches and wineries. Hear from Robert Nam, Paul Anderson, Nathan Lawre…
  continue reading
 
- Overview of the Different Names for Biomarker Testing & Why They Can Be Helpful for Treatment- Tumor Marker Testing, Genomic Profiling, Genomic Sequencing, Molecular Profiling, Next Generation Sequencing- The Relationship Between Biomarker Testing & Precision Medicine- Types of Biomarker Tests for Cancer Treatment- Do I Need Biomarker Testing for…
  continue reading
 
Interview with José P. Leone, MD, author of Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer. Hosted by Nora L. (Mary) Disis, MD. Related Content: Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer
  continue reading
 
Needle through the rectum or needle through the skin?? Transrectal vs transperienal prostate biopsy is certainly a hot topic in prostate cancer, with the vast majority of men having their biopsy through the rectum rather than through the skin. It is quick, cheap and easy (for the urologist and the health system), but leaves the patient at risk of s…
  continue reading
 
Dr Georgios Lyratzopoulos (University College London, London, UK) discusses his two papers from the International Cancer Benchmarking Partnership on the use of chemotherapy or radiotherapy in eight common cancers in Norway, the UK, Canada, and Australia. Tell us what you thought about this episode Continue this conversation on social! Follow us tod…
  continue reading
 
Two of the highest profile presentations at the recent ASCO GU Meeting were the plenary presentations of the CONTACT 02 trial, and the Keynote-564 trial. Generally speaking, these were well received; indeed quite enthusiastically received in some quarters! Not however in the quarter of prolific oncology commentator and Haematologist/Oncologist & Pr…
  continue reading
 
1. On continuation of ADT and ARAT switch 2. Systemic therapy options after progression 3. Improper mandated crossover 4. PARP inhibitors in prostate cancer Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by…
  continue reading
 
Renu caught up with lots of experts and friends at ASCO GU in San Francisco recently and brings you all the highlights. Hear from Toni Choueiri, Matt Cooperberg (on that debate on renaming low-grade prostate cancer), Todd Morgan, Neha Vapiwala, Morgan Roupret, Sophia Kamran, Morgan Roupret, Sam Washington, plus a great chat with Tyler Seibert while…
  continue reading
 
- Why Chemotherapy Causes Treatment Side Effects & Discomfort- Working with Your Healthcare Team to Better Understand & Cope with Potential Treatment Side Effects with a Plan to Manage or Prevent Them - Common Treatment Gastrointestinal (GI) Side Effects - You May Not Experience All of These - Loss of Appetite, Nausea, Vomiting, Mouth Sores, Stomat…
  continue reading
 
- Overview and Definition of Biomarkers- What Are Some Examples of Biomarker Testing- How Biomarker Testing Provides Useful Information for Cancer Treatment - Why the Molecular Portrait of Cancer Is So Important- The Role of the Pathologist- Benefits of Biomarker Testing & Precision Medicine- Predicting Response to Treatment- Clinical Trials: How R…
  continue reading
 
- Unique Needs of Young Adult Cancer Survivors- Identity, Relationships & Intimacy- Dating- Couples/Partners Dealing with Survivorship- Communicating about Sex- Sexuality & Intimacy- Sex Drive: Ability & Desire- Tips to Deal with Vaginal Dryness, Premature Menopause, Erectile Dysfunction, Premature Ejaculation & Sperm Banking- Low Desire: How to Ge…
  continue reading
 
For all you enthusiasts of PSMA theranostics, we bring you another one of our fabulous ProsTIC/Prostate Cancer Foundation Global Webinars with some of the best minds in the business. This is the eighth of our collaborative webinars over the past four years and the focus today is bringing lutetium PSMA earlier in prostate cancer. Two keynote lecture…
  continue reading
 
Loading …

Quick Reference Guide